Biotest AG: Biotest strengthens its position in the German haemophilia market with the introduction of new patient support services
News: Biotest AG / Key word(s): Miscellaneous
Biotest strengthens its position in the German haemophilia market with the introduction of new patient support services
- Biotest supports home treatment with a team of specialised nurses
- New approach aims to tailor haemophilia therapy to individual patient needs
- Biotest starts with the important haemophilia market Germany
Dreieich, 11 October 2017. Medically controlled home treatment allows patients with haemophilia to live an almost normal life and to minimise the risk of spontaneous bleeding. A prerequisite for a long-term safe treatment is a consistent and correct application of the preparations at home. With the new haemoPRO service, the support by a nurse, Biotest aims to provide patients, their relatives and caregivers with the necessary safety in the use of their haemophilia therapy. In this way, Biotest ensures that all patients are optimally treated according to their individual therapeutic scheme. The new service gives Biotest the opportunity to improve patient quality of life in its most important and largest haemophilia market in Germany.
The Biotest program haemoPRO supports where despite detailed briefings by physicians uncertainties in the correct application of the coagulation factor remain. In the haemophilia centres, the patients and their relatives are prepared for the home treatment and are extensively trained to work sterile, to properly dissolve the powder and apply intravenous injection. However, some patients and their relatives may still find it difficult to implement what has been learned in the centre in the private environment. Parents have uncertainties to find a suitable vein for their injection in their child. It is also possible that older patients are not able to inject themselves due to additional diseases. Furthermore, there are also physical limitations, such as an arm fracture, which temporarily makes a home treatment impossible.
In such and similar cases, haemoPRO's service is open to all patients treated with Biotest coagulation factors. If the patient agrees to the attendance of the haemoPRO service offered by the physician, a haemoPRO nurse will contact the patient and arrange visits. haemoPRO keeps the physician up-to-date on the training results after each contact. Thus, the patient's quality of life can be improved in close consultation with the treating physician.
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|